AMLX Amylyx Pharmaceuticals Inc
Price (delayed)
$3.3
Market cap
$226.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.82
Enterprise value
$155.49M
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a
Highlights
Amylyx Pharmaceuticals's debt has decreased by 46% YoY and by 18% from the previous quarter
AMLX's gross profit has dropped by 77% year-on-year and by 61% since the previous quarter
The gross margin has plunged by 66% YoY and by 41% from the previous quarter
Key stats
What are the main financial stats of AMLX
Market
Valuations
Earnings
Shares outstanding
68.55M
Market cap
$226.21M
Enterprise value
$155.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
1.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.79
Revenue
$196.49M
Gross profit
$62.49M
Operating income
-$272.14M
Net income
-$259.47M
EBIT
-$257.48M
EBITDA
-$256.43M
Free cash flow
-$95.58M
Per share
Balance sheet
Liquidity
EPS
-$3.82
EPS diluted
-$3.82
Free cash flow per share
-$1.4
Book value per share
$2.88
Revenue per share
$2.89
TBVPS
$3.68
Total assets
$250.71M
Total liabilities
$54.51M
Debt
$2.57M
Equity
$196.2M
Working capital
$191.35M
Debt to equity
0.01
Current ratio
4.55
Quick ratio
4.41
Net debt/EBITDA
0.28
Margins
Efficiency
Dividend
EBITDA margin
-130.5%
Gross margin
31.8%
Net margin
-132.1%
Operating margin
-138.5%
Return on assets
-68.4%
Return on equity
-85.4%
Return on invested capital
-138.7%
Return on capital employed
-130.8%
Return on sales
-131%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMLX stock price
How has the Amylyx Pharmaceuticals stock price performed over time
Intraday
-6.25%
1 week
-11.29%
1 month
-4.35%
1 year
-78.45%
YTD
-12.7%
QTD
-12.7%
Financial performance
How have Amylyx Pharmaceuticals's revenue and profit performed over time
Revenue
$196.49M
Gross profit
$62.49M
Operating income
-$272.14M
Net income
-$259.47M
Gross margin
31.8%
Net margin
-132.1%
Amylyx Pharmaceuticals's net margin has plunged by 138% from the previous quarter
The company's operating margin has shrunk by 133% QoQ
AMLX's gross profit has dropped by 77% year-on-year and by 61% since the previous quarter
The gross margin has plunged by 66% YoY and by 41% from the previous quarter
Growth
What is Amylyx Pharmaceuticals's growth rate over time
Valuation
What is Amylyx Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.15
P/S
1.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.79
AMLX's EPS has dropped by 57% since the previous quarter
The equity has dropped by 53% year-on-year and by 25% since the previous quarter
AMLX's P/B is 4.5% above its last 4 quarters average of 1.1
Amylyx Pharmaceuticals's revenue has decreased by 34% from the previous quarter and by 33% YoY
The price to sales (P/S) is 5% lower than the last 4 quarters average of 1.2
Efficiency
How efficient is Amylyx Pharmaceuticals business performance
AMLX's return on sales has dropped by 141% since the previous quarter
The company's return on invested capital has shrunk by 93% QoQ
Amylyx Pharmaceuticals's ROE has plunged by 85% from the previous quarter
Amylyx Pharmaceuticals's ROA has plunged by 79% from the previous quarter
Dividends
What is AMLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMLX.
Financial health
How did Amylyx Pharmaceuticals financials performed over time
The current ratio has dropped by 52% year-on-year and by 2.4% since the previous quarter
The quick ratio has decreased by 48% YoY
Amylyx Pharmaceuticals's debt is 99% less than its equity
The equity has dropped by 53% year-on-year and by 25% since the previous quarter
Amylyx Pharmaceuticals's debt has decreased by 46% YoY and by 18% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.